CN101274031A - 一种治疗肠易激综合征的药物组合物 - Google Patents
一种治疗肠易激综合征的药物组合物 Download PDFInfo
- Publication number
- CN101274031A CN101274031A CNA200710095916XA CN200710095916A CN101274031A CN 101274031 A CN101274031 A CN 101274031A CN A200710095916X A CNA200710095916X A CN A200710095916XA CN 200710095916 A CN200710095916 A CN 200710095916A CN 101274031 A CN101274031 A CN 101274031A
- Authority
- CN
- China
- Prior art keywords
- oleum
- pharmaceutical composition
- citri reticulatae
- irritable bowel
- bowel syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000002551 irritable bowel syndrome Diseases 0.000 title claims abstract description 19
- 239000003814 drug Substances 0.000 title description 18
- 239000000203 mixture Substances 0.000 title description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 38
- 230000000968 intestinal effect Effects 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 14
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims description 16
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 claims description 12
- 239000002552 dosage form Substances 0.000 claims description 9
- 229940087305 limonene Drugs 0.000 claims description 8
- 235000001510 limonene Nutrition 0.000 claims description 8
- 239000007901 soft capsule Substances 0.000 claims description 7
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 claims description 6
- 239000005770 Eugenol Substances 0.000 claims description 6
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 claims description 6
- 229960002217 eugenol Drugs 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 3
- 241000628997 Flos Species 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 206010012735 Diarrhoea Diseases 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 10
- 244000223014 Syzygium aromaticum Species 0.000 abstract description 3
- 230000013872 defecation Effects 0.000 abstract description 3
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 2
- 230000007423 decrease Effects 0.000 abstract description 2
- 241000675108 Citrus tangerina Species 0.000 abstract 2
- 102000003797 Neuropeptides Human genes 0.000 abstract 1
- 108090000189 Neuropeptides Proteins 0.000 abstract 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 abstract 1
- 230000002421 anti-septic effect Effects 0.000 abstract 1
- 239000010634 clove oil Substances 0.000 abstract 1
- 210000003608 fece Anatomy 0.000 abstract 1
- 239000003629 gastrointestinal hormone Substances 0.000 abstract 1
- 239000003921 oil Substances 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 20
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- 230000037396 body weight Effects 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 241000700159 Rattus Species 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 235000019341 magnesium sulphate Nutrition 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical class [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 238000012449 Kunming mouse Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- ALWKGYPQUAPLQC-UHFFFAOYSA-N neostigmine Chemical compound CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 ALWKGYPQUAPLQC-UHFFFAOYSA-N 0.000 description 6
- 229960002362 neostigmine Drugs 0.000 description 6
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 4
- 230000018044 dehydration Effects 0.000 description 4
- 238000006297 dehydration reaction Methods 0.000 description 4
- 210000005069 ears Anatomy 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 210000001187 pylorus Anatomy 0.000 description 4
- 239000013558 reference substance Substances 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000007750 drug combination effect Effects 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000001256 steam distillation Methods 0.000 description 3
- 230000009278 visceral effect Effects 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 2
- 229920001268 Cholestyramine Polymers 0.000 description 2
- 241001672694 Citrus reticulata Species 0.000 description 2
- 240000007311 Commiphora myrrha Species 0.000 description 2
- 235000006965 Commiphora myrrha Nutrition 0.000 description 2
- 206010014025 Ear swelling Diseases 0.000 description 2
- 208000004232 Enteritis Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 235000007265 Myrrhis odorata Nutrition 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical group O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 2
- 229960003727 granisetron Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 229960005343 ondansetron Drugs 0.000 description 2
- 230000001141 propulsive effect Effects 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 206010028140 Mucous stools Diseases 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- 208000033039 Somatisation disease Diseases 0.000 description 1
- 208000027520 Somatoform disease Diseases 0.000 description 1
- 108050001286 Somatostatin Receptor Proteins 0.000 description 1
- 102000011096 Somatostatin receptor Human genes 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- KNDHRUPPBXRELB-UHFFFAOYSA-M [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride Chemical compound [Cl-].C1=CC(CC)=CC=C1C(C)CCC1=CC=C([N+](C)(C)C)C=C1 KNDHRUPPBXRELB-UHFFFAOYSA-M 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 229960001678 colestyramine Drugs 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- MVKIWCDXKCUDEH-QFIPXVFZSA-N fedotozine Chemical compound C([C@](CC)(N(C)C)C=1C=CC=CC=1)OCC1=CC(OC)=C(OC)C(OC)=C1 MVKIWCDXKCUDEH-QFIPXVFZSA-N 0.000 description 1
- 229950008449 fedotozine Drugs 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 239000005350 fused silica glass Substances 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000007149 gut brain axis pathway Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 208000016994 somatization disease Diseases 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA200710095916XA CN101274031A (zh) | 2007-03-28 | 2007-03-28 | 一种治疗肠易激综合征的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA200710095916XA CN101274031A (zh) | 2007-03-28 | 2007-03-28 | 一种治疗肠易激综合征的药物组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101274031A true CN101274031A (zh) | 2008-10-01 |
Family
ID=39994167
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA200710095916XA Pending CN101274031A (zh) | 2007-03-28 | 2007-03-28 | 一种治疗肠易激综合征的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101274031A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103223045A (zh) * | 2013-04-08 | 2013-07-31 | 张宗升 | 中药组合物 |
CN104288731A (zh) * | 2014-10-17 | 2015-01-21 | 徐春娟 | 外贴肚脐治疗消化不良中药制剂 |
CN108042635A (zh) * | 2018-02-08 | 2018-05-18 | 翔宇药业股份有限公司 | 用于治疗体癣的制剂的制备工艺 |
-
2007
- 2007-03-28 CN CNA200710095916XA patent/CN101274031A/zh active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103223045A (zh) * | 2013-04-08 | 2013-07-31 | 张宗升 | 中药组合物 |
CN104288731A (zh) * | 2014-10-17 | 2015-01-21 | 徐春娟 | 外贴肚脐治疗消化不良中药制剂 |
CN108042635A (zh) * | 2018-02-08 | 2018-05-18 | 翔宇药业股份有限公司 | 用于治疗体癣的制剂的制备工艺 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100358549C (zh) | 一种治疗腹泻病的中药组合物 | |
CN101919913B (zh) | 一种具有治疗类风湿关节炎作用的组合物 | |
JP2022001572A (ja) | 漢方処方菌叢カプセル、その製造方法、及び2型糖尿病の治療薬の製造における漢方処方菌叢カプセルの使用 | |
CN101703684B (zh) | 一种治疗过敏性紫癜的药物及其制备方法 | |
CN101167937A (zh) | 一种治疗风湿或类风湿的中药组合物贴膏及其制备方法 | |
CN101274031A (zh) | 一种治疗肠易激综合征的药物组合物 | |
CN105106228B (zh) | 用作TMEM16A离子通道激活剂的含人参皂苷Rb1的药物组合物 | |
CN101991811B (zh) | 一种治疗风湿关节疼痛、感冒头痛、脘腹疼痛、冻疮的中药组合物及其制备方法 | |
CN101181285A (zh) | 黄芪甲苷在制备治疗神经退行性疾病药物中的应用 | |
CN103356630B (zh) | 含有己酮可可碱和普卡必利的药物组合物及其医药用途 | |
JP7157253B2 (ja) | 潤腸便通の漢方薬組成物、その調製方法及びその用途 | |
CN1833687A (zh) | 一种用于治疗消化性溃疡和慢性胃炎的中药组合物及其制备方法和其用途 | |
CN100475236C (zh) | 一种治疗妇科盆腔炎的药物组合物及其制备方法和用途 | |
CN100455309C (zh) | 一种治疗妇科炎症的复方中药制剂及其制备方法 | |
CN101168050B (zh) | 免疫调节药物组合物 | |
CN103908567A (zh) | 一种用于治疗糖尿病痛性神经病变的复方制剂及其应用 | |
CN104042928A (zh) | 一种治疗糖尿病的药物组合物及其制备方法和用途 | |
CN108175793A (zh) | 一种兽药组合物及其制备方法和应用 | |
US9358265B2 (en) | Plant based formulation for the prevention and management of irritable bowel syndrome (IBS) | |
CN103893447B (zh) | 一种治疗前列腺炎的药物及其制备方法 | |
CN104491637B (zh) | 一种治疗感冒后咳嗽的复方组合药物及其制备方法与应用 | |
CN112691167B (zh) | 一种治疗抑郁症的中药组合物及其制剂和应用 | |
CN1301125C (zh) | 一种治疗胃肠道疾病的药物 | |
Gong et al. | The synergistic effects of Bupleuri radix with Citri Reticulatae Pericarpium and Aurantii Fructus on the improvement of gastrointestinal function | |
CN104740312B (zh) | 一种用于治疗慢性胃炎的中药组合物及其制备和检测方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Owner name: CHEN JIN Free format text: FORMER OWNER: HEKANG PHARMACEUTICAL LLC, CHENGDU Effective date: 20090508 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20090508 Address after: Room 420, Goldman Sachs center, No. 2 Gaosheng East Road, Sichuan, Chengdu Applicant after: Chen Jin Address before: High tech Zone of Chengdu City, Sichuan Province, Gaopeng Road No. 2 Applicant before: Hekang Medicine Industry Co., Ltd., Chengdu |
|
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Chen Jin Document name: Notification of Passing Examination on Formalities |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20081001 |